CoChat

A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma

Open access
Horvilleur, E, Sbarrato, T, Hill, K, Spriggs, R V, Screen, M, Goodrem, P J, Sawicka, K, Chaplin, L C, Touriol, C, Packham, G, Potter, K N, Dirnhofer, S, Tzankov, A, Dyer, M J S, Bushell, M, MacFarlane, M, Willis, A E · 2014 · Leukemia
Cited by 74

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Dysregulated expression of factors that control protein synthesis is associated with poor prognosis of many cancers, but the underlying mechanisms are not well defined. Analysis of the diffuse large B-cell lymphoma (DLBCL) translatome revealed selective upregulation of mRNAs encoding anti-apoptotic and DNA repair proteins. We show that enhanced synthesis of these proteins in DLBCL is mediated by the relief of repression that is normally imposed by structure in the 5'-untranslated regions of their corresponding mRNAs. This process is driven by signaling through mammalian target of rapamycin, resulting in increased synthesis of eukaryotic initiation factor (eIF) 4B complex (eIF4B), a known activator of the RNA helicase eIF4A. Reducing eIF4B expression alone is sufficient to decrease synthesis of proteins associated with enhanced tumor cell survival, namely DAXX, BCL2 and ERCC5. Importantly, eIF4B-driven expression of these key survival proteins is directly correlated with patient outcome, and eIF4B, DAXX and ERCC5 are identified as novel prognostic markers for poor survival in DLBCL. Our work provides new insights into the mechanisms by which the cancer-promoting translational machinery drives lymphomagenesis.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/leu.2013.295

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Research works printed but not linked: 42

  1. Stoneley M, Willis AE . Aberrant regulation of translation initiation in tumorigenesis. Curr Mol Med 2003; 3: 597–603. · DOI
  2. Braunstein S, Karpisheva K, Pola C, Goldberg J, Hochman T, Yee H et al. A hypoxia-controlled cap-dependent to cap-independent translation switch in breast cancer. Mol Cell 2007; 28: 501–512. · DOI · Paper page
  3. Le Quesne JP, Spriggs KA, Bushell M, Willis AE . Dysregulation of protein synthesis and disease. J Pathol 2010; 220: 140–151. · DOI
  4. Sonenberg N, Hinnebusch AG . Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009; 136: 731–745. · DOI · Paper page
  5. Bushell M, Wood W, Carpenter G, Pain VM, Morley SJ, Clemens MJ . Disruption of the interaction of mammalian protein synthesis eukaryotic initiation factor 4B with the poly(A)-binding protein by caspase- and viral protease-mediated cleavages. J Biol Chem 2001; 276: 23922–23928. · DOI · Paper page
  6. Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N . eIF4E—from translation to transformation. Oncogene 2004; 23: 3172–3179. · DOI · Paper page
  7. Averous J, Proud CG . When translation meets transformation: the mTOR story. Oncogene 2006; 25: 6423–6435. · DOI · Paper page
  8. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511. · DOI · Paper page
  9. Bea S, Zettl A, Wright G, Salaverria I, Jehn P, Moreno V et al. Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction. Blood 2005; 106: 3183–3190. · DOI · Paper page
  10. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285–2290. · DOI · Paper page
  11. Rosenwald A, Staudt LM . Gene expression profiling of diffuse large B-cell lymphoma. Leuk Lymphoma 2003; 44 (Suppl 3): S41–S47. · DOI · Paper page
  12. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947. · DOI · Paper page
  13. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, De Leval L et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102: 3871–3879. · DOI · Paper page
  14. Friedberg JW . New strategies in diffuse large B-cell lymphoma: Translating findings from gene expression analyses into clinical practice. Clin Cancer Res 2011; 17: 6112–6117. · doi:10.1158/1078-0432.ccr-11-1073
  15. Li JJ, Bickel PJ, Biggin MD . System wide analyses have underestimated protein abundances and transcriptional importance in mammals, arXiv.org eprint archive, arXiv:1212.0587v6. · arXiv
  16. Clemens MJ, Bushell M, Morley SJ . Degradation of eukaryotic polypeptide chain initiation factor (eIF) 4G in response to induction of apoptosis in human lymphoma cell lines. Oncogene 1998; 17: 2921–2931. · DOI · Paper page
  17. West MJ, Stoneley M, Willis AE . Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998; 17: 769–780. · DOI · Paper page
  18. Horvilleur E, Bauer M, Goldschneider D, Mergui X, de la Motte A, Benard J et al. p73alpha isoforms drive opposite transcriptional and post-transcriptional regulation of MYCN expression in neuroblastoma cells. Nucleic Acids Res 2008; 36: 4222–4232. · DOI
  19. Smyth GK, Michaud J, Scott HS . Use of within-array replicate spots for assessing differential expression in microarray experiments. Bioinformatics 2005; 21: 2067–2075. · DOI · Paper page
  20. Breitling R, Armengaud P, Amtmann A, Herzyk P . Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett 2004; 573: 83–92. · DOI · Paper page
  21. Hong F, Breitling R, McEntee CW, Wittner BS, Nemhauser JL, Chory J . RankProd: a bioconductor package for detecting differentially expressed genes in meta-analysis. Bioinformatics 2006; 22: 2825–2827. · DOI · Paper page
  22. Obermann EC, Went P, Zimpfer A, Tzankov A, Wild PJ, Stoehr R et al. Expression of minichromosome maintenance protein 2 as a marker for proliferation and prognosis in diffuse large B-cell lymphoma: a tissue microarray and clinico-pathological analysis. BMC Cancer 2005; 5: 162. · doi:10.1186/1471-2407-5-162
  23. Remmele W, Stegner HE . [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. Pathologe 1987; 8: 138–140.
  24. Therneau TM, Li H . Computing the Cox model for case cohort designs. Lifetime Data Anal 1999; 5: 99–112. · DOI · Paper page
  25. Lorenz WA, Clote P . Computing the partition function for kinetically trapped RNA secondary structures. PLoS One 2011; 6: e16178. · DOI
  26. Kramer MH, Hermans J, Parker J, Krol AD, Kluin-Nelemans JC, Haak HL et al. Clinical significance of bcl2 and p53 protein expression in diffuse large B-cell lymphoma: a population-based study. J Clin Oncol 1996; 14: 2131–2138. · DOI · Paper page
  27. Park EH, Zhang F, Warringer J, Sunnerhagen P, Hinnebusch AG . Depletion of eIF4G from yeast cells narrows the range of translational efficiencies genome-wide. BMC Genomics 2011; 12: 68. · DOI · Paper page
  28. Blagden SP, Willis AE . The biological and therapeutic relevance of mRNA translation in cancer. Nat Rev Clin Oncol 2011; 8: 280–291. · DOI
  29. Rogers GW Jr, Richter NJ, Lima WF, Merrick WC . Modulation of the helicase activity of eIF4A by eIF4B, eIF4H, and eIF4F. J Biol Chem 2001; 276: 30914–30922. · DOI · Paper page
  30. Shahbazian D, Parsyan A, Petroulakis E, Topisirovic I, Martineau Y, Gibbs BF et al. Control of cell survival and proliferation by mammalian eukaryotic initiation factor 4B. Mol Cell Biol 2010; 30: 1478–1485. · DOI · Paper page
  31. Sebestyen A, Sticz TB, Mark A, Hajdu M, Timar B, Nemes K et al. Activity and complexes of mTOR in diffuse large B-cell lymphomas—a tissue microarray study. Mod Pathol 2012; 25: 1623–1628. · DOI
  32. Tsujimoto Y, Bashir MM, Givol I, Cossman J, Jaffe E, Croce CM . DNA rearrangements in human follicular lymphoma can involve the 5' or the 3' region of the bcl-2 gene. Proc Natl Acad Sci USA 1987; 84: 1329–1331. · DOI
  33. Buggins AG, Pepper CJ . The role of Bcl-2 family proteins in chronic lymphocytic leukaemia. Leuk Res 2010; 34: 837–842. · DOI
  34. Barrans SL, Carter I, Owen RG, Davies FE, Patmore RD, Haynes AP et al. Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma. Blood 2002; 99: 1136–1143. · DOI · Paper page
  35. Perlman R, Schiemann WP, Brooks MW, Lodish HF, Weinberg RA . TGF-beta-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation. Nat Cell Biol 2001; 3: 708–714. · DOI · Paper page
  36. Yang X, Khosravi-Far R, Chang HY, Baltimore D . Daxx, a novel Fas-binding protein that activates JNK and apoptosis. Cell 1997; 89: 1067–1076. · DOI · Paper page
  37. Chen LY, Chen JD . Daxx silencing sensitizes cells to multiple apoptotic pathways. Mol Cell Biol 2003; 23: 7108–7121. · DOI · Paper page
  38. Jiao Y, Shi C, Edil BH, de Wilde RF, Klimstra DS, Maitra A et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011; 331: 1199–1203. · DOI · Paper page
  39. Kramer MH, Hermans J, Wijburg E, Philippo K, Geelen E, van Krieken JH et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood 1998; 92: 3152–3162. · DOI · Paper page
  40. Dunleavy K, Wilson WH . Differential role of BCL2 in molecular subtypes of diffuse large B-cell lymphoma. Clin Cancer Res 2011; 17: 7505–7507. · DOI
  41. Lord CJ, Ashworth A . Bringing DNA repair in tumors into focus. Clin Cancer Res 2009; 15: 3241–3243. · DOI
  42. Witzens-Harig M, Memmer ML, Dreyling M, Hess G . A phase I/II trial to evaluate the safety, feasibility and activity of salvage therapy consisting of the mTOR inhibitor Temsirolimus added to standard therapy of Rituximab and DHAP for the treatment of patients with relapsed or refractory diffuse large cell B-Cell lymphoma - the STORM trial. BMC Cancer 2013; 13: 308. · DOI

Cited by

See all 74

Metadata

Authors
Horvilleur, E., Sbarrato, T., Hill, K., Spriggs, R. V., Screen, M., Goodrem, P. J., Sawicka, K., Chaplin, L. C., Touriol, C., Packham, G., Potter, K. N., Dirnhofer, S., Tzankov, A., Dyer, M. J. S., Bushell, M., MacFarlane, M., & Willis, A. E.
Venue
Leukemia
Published
2013-10-18
Volume
28
Issue
5
Pages
1092-1102
ISSN
  • 0887-6924 (ISSN-L)
  • 1476-5551
OpenAlex
W1991312668
Cited by
74
References
9
FWCI
2.69
Type
journal article
Language
en
Open access
hybrid
Licence
creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. https://app.cochat.ai/papers/10.1038/leu.2013.295
The paper
Horvilleur, E., Sbarrato, T., Hill, K., Spriggs, R. V., Screen, M., Goodrem, P. J., Sawicka, K., Chaplin, L. C., Touriol, C., Packham, G., Potter, K. N., Dirnhofer, S., Tzankov, A., Dyer, M. J. S., Bushell, M., MacFarlane, M., & Willis, A. E. (2014). A role for eukaryotic initiation factor 4B overexpression in the pathogenesis of diffuse large B-cell lymphoma. Leukemia. https://doi.org/10.1038/leu.2013.295

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.